Ajanta Pharma Management Guidance Tracker
12 forward-looking guidance items tracked across 3 quarters.
Margins
Management reiterated EBITDA margin guidance of 27% ±1% for the remaining two quarters, excluding forex mark-to-market impact.
Q3 FY26FY26 EBITDA margin guidance of 27%±1%ActiveManagement reiterated EBITDA margin guidance of 27%±1% for the full year, excluding forex mark-to-market impact.
Q3 FY26FY26 gross margin guidance of 78%±1%ActiveGross margin expected to remain around 78%±1% for the full year.
Q4 FY26EBITDA margin ~27% ±1% for FY27TrackedManagement guided EBITDA margin of 27% with a variation of plus/minus 1%, factoring in investments, higher freight costs, and R&D spending.
Revenue
Management expects US generics to maintain the current quarterly run-rate of ~₹343 crore for the next two quarters.
Q2 FY26Africa business upgraded to double-digit growth for FY26ActiveManagement upgraded Africa growth guidance from mid-single-digit to double-digit for the full year, citing favorable base effect.
Q4 FY26Revenue growth 16-18% for FY27TrackedOverall company revenue expected to grow 16-18% in FY27, driven by high double-digit growth in Asia and Africa branded generics, mid-single-digit US growth, and India outperformance.
Capex
Capex incurred ₹145 crore in H1; full-year capex expected to be ₹300 crore as guided earlier.
Q3 FY26FY26 capex guidance of ~₹300 croreActiveCapital expenditure for FY26 expected to be around ₹300 crore, with ₹235 crore spent in 9 months.
Q4 FY26Capex of ~₹400 crore in FY27TrackedCapital expenditure expected to increase to around ₹400 crore, including ₹150 crore maintenance and ₹250 crore for capacity expansion.